» Articles » PMID: 15961287

Increased Nicotine and Cotinine Levels in Smokers with Schizophrenia and Schizoaffective Disorder is Not a Metabolic Effect

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2005 Jun 18
PMID 15961287
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

It has been hypothesized that smokers with schizophrenia take in more nicotine per cigarette than smokers without this disorder. This study examines this phenomenon by comparing the serum nicotine and cotinine levels in smokers with either schizophrenia or schizoaffective disorder compared to control smokers without mental illness. Serum cotinine and nicotine levels of smokers with schizophrenia or schizoaffective disorder were 1.3 times higher than control smokers (cotinine 291 versus 227 ng/mL; p = 0.0115; nicotine 28 versus 21 ng/mL; p < 0.001) despite smoking a similar number of cigarettes per day. Similar serum 3'-hydroxycotinine (3HC) to cotinine ratios in both groups indicate that this difference was not due to differences in the rate of metabolism of nicotine or cotinine. By examining serum nicotine and 3HC/cotinine ratios in addition to cotinine, this study expands upon previous research that relied on cotinine as an indirect indicator for nicotine intake. Our data support the hypothesis that the increased serum nicotine and cotinine levels observed are attributable to an increased nicotine intake per cigarette in smokers with schizophrenia as compared to those without mental illness.

Citing Articles

Implementation of the healthy heart tool- an algorithm with potential cardiometabolic health benefits in persons with severe mental illness.

Lund-Stenvold E, Ringen P, Andreassen O, Gaarden T, Hartberg C, Johnsen E BMC Psychiatry. 2025; 25(1):172.

PMID: 40001014 PMC: 11863842. DOI: 10.1186/s12888-025-06578-w.


Smoking affects symptom improvement in schizophrenia: a prospective longitudinal study of male patients with first-episode schizophrenia.

Mu X, Wu W, Wang S, Su X, Guan H, Guan X Schizophrenia (Heidelb). 2024; 10(1):34.

PMID: 38491003 PMC: 10943037. DOI: 10.1038/s41537-024-00449-1.


Comparison of outcomes for patients with and without a serious mental illness presenting to hospital for chronic obstruction pulmonary disease: retrospective observational study using administrative data.

Goldman S, Saoulidi A, Kalidindi S, Kravariti E, Gaughran F, Briggs T BJPsych Open. 2023; 9(4):e128.

PMID: 37458249 PMC: 10375884. DOI: 10.1192/bjo.2023.522.


Smoking Affects the Predictive Roles of Antioxidant Enzymes in the Clinical Response to Risperidone in Schizophrenia: A Large-scale Cohort Study.

Xiu M, Song X, Yang H, Huang X, Wu F, Zhang X Curr Neuropharmacol. 2023; 21(10):2151-2158.

PMID: 37132112 PMC: 10556368. DOI: 10.2174/1570159X21666230502125800.


The cost-effectiveness of tailored smoking cessation interventions for people with severe mental illness: a model-based economic evaluation.

Mattock R, Owen L, Taylor M EClinicalMedicine. 2023; 57:101828.

PMID: 36798753 PMC: 9925867. DOI: 10.1016/j.eclinm.2023.101828.